|
Clinical Trials for Mast Cell Tumors |
|
|
|
DOGS WITH MAST CELL TUMORS #1
Eligibility Requirements
• Dogs with confirmed MCT, with or without lymph node involvement, may be eligible for this study. Prior surgery for MCT is acceptable, but no previous medical therapy (steroids, chemotherapy, etc.) is permitted
Study Objective
we are seeking to investigate the difference in responses of MCT with and without a mutation in KIT to Palladia and vinblastine
Compensation
The study will pay for the initial biopsy, KIT genotyping (to determine mutation status), chemistry profiles, and costs associated with treatment (Palladia or vinblastine). The owner will be responsible for the costs of the initial examination and tests to insure eligibility to participate (approximately $400), the recheck examinations, complete blood counts, and ancillary medications (Benadryl, omeprazole, prednisone). Please click on the link for more details.
Location of Trial
Madison, Wisconsin
More information
DOGS WITH MAST CELL TUMORS #2
Eligibility Requirements
• Dogs with confirmed MCT, with or without lymph node involvement, may be eligible for this study. Prior surgery and chemotherapy for MCT is acceptable with the exception of prior treatment with Palladia or lomustine. Dogs that have received Palladia or lomustine are not eligible for this study. All dogs will receive Palladia and lomustine. The dose of lomustine will be increased as dogs are entered into this trial so that we can determine the maximum tolerated dose of lomustine when given in combination with Palladia.
Study Objective
we are investigating the combination of Palladia and lomustine
Compensation
The study will pay for the costs associated with treatment (Palladia and lomustine), and physical examinations and blood tests required throughout treatment. The owner will be responsible for the costs of the initial examination and tests to insure eligibility to participate (approximately $400) and ancillary medications (Benadryl, omeprazole, prednisone). Please click on the link for more details.
Location of Trial
Madison, Wisconsin
More information
Pharmacokinetics of vinblastine in dogs with mast cell tumors.
Eligibility Requirements
• Dogs with confirmed mast cell tumor that are clinically well are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete blood count and chemistry profile). They must have acceptable blood cell counts and be healthy enough to undergo chemotherapy.
Study Objective
Mast cell tumor is a common skin tumor of dogs. Current treatment options available for mast cell tumor include various combinations of surgery, chemotherapy drugs such as vinblastine or lomustine, radiation therapy, and the new oral mast cell tumor drug Palladia® (toceranib). Vinblastine is an intravenous chemotherapy agent that is commonly used in the treatment of mast cell tumors. The aim of this study is to determine the concentration of the drug in the blood at different times following intravenous administration. This information has not yet been established in dogs and may vary among individuals. Information gained from this study will help us determine the pharmacokinetics of vinblastine and may help us tailor vinblastine doses for individual patients in the future.
Compensation
The owner is responsible for scheduling appointments with the oncology clinical trials coordinator and keeping those appointments as required by study protocol. The owner is responsible for the costs of diagnosis and staging of the mast cell tumor prior to entering the study. Clients participating in this study will be given special financial considerations. Specifically, the study will pay for the costs associated with the study, hospitalization as well as cost and administration of the vinblastine. Additionally a $100 credit will be applied the client’s hospital account.
Location of Trial
Fort Collins, CO
More information
c-Kit Mutation and Localization Status as Response Predictors in Canine Mast Cell Tumors Treated with Palladia® (toceranib) or Vinblastine: A Response-Adaptive Randomized Trial
Eligibility Requirements
INCLUSION CRITERIA
• Dogs with cytologically or histologically confirmed, measurable cutaneous or subcutaneous mast cell tumor, with or without lymph node involvement.
• Diagnostic testing to ensure eligibility includes: bloodwork (complete blood count and chemistry profile), regional lymph node aspirate, thoracic radiographs, and abdominal ultrasound.
• Dogs must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying disease.
• Prior surgery for mast cell tumor is acceptable.
EXCLUSION CRITERIA
• No previous chemotherapy is permitted.
OWNER RESPONSIBILITY
• Responsible for the cost of diagnosing and staging the mast cell tumor prior to entering the study.
• Expected to make and keep all appointments according to the study protocol.
• They must be comfortable administering oral medications at home.
• They must be committed to completing the entire study protocol and follow-up examinations
Compensation
Clients participating in this study will be given special financial considerations. The study will pay for the initial biopsy, KIT genotyping (to determine mutation status), chemistry profiles, and costs associated with treatment (Palladia® or vinblastine). The owner will be responsible for the costs of the consult (initial) examination and tests to insure eligibility to participate, the recheck examinations, complete blood counts, and ancillary medications (Benadryl, omeprazole, prednisone).
Location of Trial
Red Bank, NJ
More information
Pulse Palladia plus CCNU for the Treatment of Measurable Canine Mast Cell Tumors
Eligibility Requirements
• Dogs with measurable mast cell tumors.
Study Objective
The goal of the current study is to evaluate the combination of conventional CCNU chemotherapy with Palladia in hopes of improving outcome for dogs with mast cell tumors. This study will also determine the optimal dosage of combined CCNU and Palladia in dogs.
Compensation
The study will provide the chemotherapy drugs CCNU and Palladia and will cover the majority of costs of blood work performed as part of treatment monitoring. Clients will be responsible for costs associated with initial evaluation, recheck visit evaluations, and any concurrent medications. Please click on the link for more details
Location of Trial
Raleigh, NC
More information
Palladia vs. vinblastine in canine mast cell tumors.
Eligibility Requirements
• Dogs with confirmed mast cell tumor, with or without lymph node involvement, are eligible for this study. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible, including bloodwork (complete blood count and chemistry profile), regional lymph node aspirate, thoracic radiographs, and abdominal ultrasound. They must have good function of liver and kidneys, have acceptable blood cell counts, and are free of severe underlying disease. Prior surgery for mast cell tumor is acceptable, but no previous chemotherapy is permitted.
Study Objective
TThrough this clinical trial, we are seeking to investigate the difference in responses of mast cell tumors with and without a mutation in KIT to Palladia and vinblastine.
Compensation
Clients participating in this study will be given special financial considerations. The study will pay for the initial biopsy, KIT genotyping (to determine mutation status), chemistry profiles, and costs associated with treatment (Palladia or vinblastine). The owner will be responsible for the costs of the initial examination and tests to insure eligibility to participate, the recheck examinations, complete blood counts, and ancillary medications (Benadryl, omeprazole, prednisone). Please click on the link for more details
Location of Trial
Fort Collins, CO
Davis, CA
CCB02. The National Cancer Institute and UCDAVIS
Eligibility Requirements
• Confirmed diagnosis
• Physical examination with weight recorded
Study Objective
The National Cancer Institute is looking for Golden Retrievers with Lymphoma, Osteosarcoma, Mast Cell Tumors, and Hemangiosarcoma to participate in a clinical trial
Compensation
If your Golden Retriever is eligible for any of the above mentioned cancer types, the study will pay for full-staging (CBC, Chemistry panel, Urine Analysis, Ultrasound, Radiographs) $800-$1000 of staging. This is not a therapy, chemo or drug study. It is a tissue collection study to populate the tissue bank for future research. After your pets surgery you will be instructed to follow-up with an oncologist or your local veterinarian for follow-up care.
Location of Trial
Davis , CA
More information
Treatment of mast cell tumors with palladia and CCNU.
Eligibility Requirements
• Certain criteria determine patient eligibility. Dogs with microscopically confirmed, measurable mast cell tumors are potentially eligible for this study. Spread of the cancer (known as “metastasis”) is allowed, if the patient is expected to survive at least 6 weeks. Patients must be free of other severe diseases. Dogs must undergo some diagnostic testing prior to starting the study to ensure that they are eligible. They must have good function of liver and kidneys and have acceptable blood cell counts.
Study Objective
The purpose of this study is to determine if using Palladia in combination with CCNU will have better anti-tumor effect for dogs with mast cell tumors than CCNU used as a sole treatment.
Compensation
There are no financial incentives associated with this study. Please click on the link for more details.
Location of Trial
Fort Collins, CO
More information
Palladia™/Vinblastine for Canine Mast Cell Tumor
Eligibility Requirements
• Have a confirmed diagnosis of a mast cell tumor
• Initial evaluation which may include radiographs, CBC, chemistry profile & UA
• No concurrent chemotherapy (within 3 weeks) or radiation therapy or any corticosteroid/nonsteroidal anti-inflammatory within 72 hours of study entry.
• Dog must weigh a minimum of 10 kg
• Free of any serious systemic disorder incompatible with this study
Study Objective
Palladia™ and Vinblastine have each (individually) been extensively studied in normal and in dogs with cancer. Both drugs have been shown to have anti-cancer activity in dogs with mast cell tumors. The purpose of this study is to evaluate the safety and anti-cancer activity when these drugs are administered in combination.
Compensation
Free Toceranib phosphate (Palladia™), and Vinblastine. Costs of office calls, CBC’s, chemistry panels, and UA for the 4 weeks of vinblastine treatments. Please click on link for more details.
Location of Trial
University of Missouri
More information
Phase I Clinical Trial of Vinorelbine in Tumor- Bearing Cats
Eligibility Requirements
• Cats with any cytologically or histologically confirmed cancer are eligible.
• They may have measureable or microscopic disease to participate.
• They may have had prior surgery, radiotherapy. and/or chemotherapy. However, there must be at least a four week lapse between any of these treatments and entry into the trial.
• Cats may not receive non-steroidal anti-inflammatory drugs (NSAIDS) or steroids while in the study and must undergo a 72 hours washout period if on NSAIDS or steroids prior to stduy initiation.
• They must have normal organ and bone marrow function and have an expected survival of at least 4 weeks.
• Owners must sign a consent form.
Study Objective
To determine the dose-limiting toxicity and maximum tolerated dosage, to establish a safe starting dosage, and to elucidate treatment-related side effects of Vinorelbine in tumor-bearing cats.
Compensation
Cost of intial tests, chemotherapy and follow-up CBC will be reimbursed if the cat qualifies for the study.Assuming the cat tolerates the dosage well, treatments may be continue every other week, off-study, at the owners expense. Complications of chemotherapy will NOT be covered by the study. Please click on link for more details.
Location of Trial
Athens, GA
More information
Hypofractionated radiation therapy plus palladia for unresectable canine mast cell tumors (this study is set to begin by the end of summer 2010)
Eligibility Requirements
• Dogs must have histologically or cytologically confirmed, cutaneous/subcutaneous MCT
• Dogs must have adequate organ function
• Dogs must have NOT been treated with in 3 weeks with chemotherapy
Study Objective
The purpose of this study is to determine whether the addition of radiation therapy to Palladia will result in the higher likelihood of tumor shrinkage, and/or a longer duration of improvement.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbus, OH
More information
Phase Ib study of GS-424044 in dogs with malignant neoplasia
Eligibility Requirements
• Dogs with advanced solid tumors (mainly carcinomas and sarcomas)
• Dogs with tumor type confirmed by histology (for solid tumors)
• Dogs must weigh at least 10.0kg
• Dogs must be otherwise healthy and at least one year of age.
• Have adequate organ function as specified by standard laboratory tests
Study Objective
The purpose of this study is to investigate a new chemotherapy drug as treatment for dos with malignant tumors.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Athens, GA
More information
Canine patients with osteosarcoma, lymphoma, or oral malignant melanoma, mast cell tumors, soft tissue sarcomas/histiocytic sarcoma/malignant histiocytosis, primary pulmonary cancer, hemangiosarcomas
Eligibility Requirements
• Requirements vary for each type of cancer listed above. Please click on link for more details.
Study Objective
The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Davis, CA: More Information
North Grafton, MA: More Information
Madison, WI: More Information
Satraplatin for any tumor, including lymphoma
Eligibility Requirements
• Any tumor, including lymphoma confirmed by histopathology or cytology
Study Objective
To determine efficacy of using Satraplatin for various types of cancer using 5mg/m2 daily (orally).
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Columbia, MO
More information
|
| |
|
